<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Einstein (Sao Paulo)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Einstein (Sao Paulo)</journal-id>
      <journal-id journal-id-type="publisher-id">eins</journal-id>
      <journal-title-group>
        <journal-title>Einstein</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1679-4508</issn>
      <issn pub-type="epub">2317-6385</issn>
      <publisher>
        <publisher-name>Instituto Israelita de Ensino e Pesquisa Albert Einstein</publisher-name>
        <publisher-loc>Sao Paulo</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24728254</article-id>
      <article-id pub-id-type="pmc">4898247</article-id>
      <article-id pub-id-type="publisher-id">S1679-45082014RC2657</article-id>
      <article-id pub-id-type="doi">10.1590/S1679-45082014RC2657</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Normalization of lymphocyte count after high ablative dose of I-131 in a patient with chronic lymphoid leukemia and secondary papillary carcinoma of the thyroid. Case report</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Normaliza&#xE7;&#xE3;o da contagem de linf&#xF3;citos ap&#xF3;s dose ablativa de I-131 em um paciente com leucemia linf&#xF3;ide cr&#xF4;nica e carcinoma papil&#xED;fero da tire&#xF3;ide. Relato de caso</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Thom</surname>
            <given-names>Anneliese Rosmarie Gertrud Fischer</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hamerschlak</surname>
            <given-names>Nelson</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Teles</surname>
            <given-names>Ver&#xF4;nica Goes</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Osawa</surname>
            <given-names>Akemi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Santos</surname>
            <given-names>Fabio Pires de Souza</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pasqualin</surname>
            <given-names>Denise da Cunha</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wagner</surname>
            <given-names>Jairo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yamaga</surname>
            <given-names>Lilian Yuri Itaya</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>da Cunha</surname>
            <given-names>Marcelo Livorsi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Campos</surname>
            <given-names>Guilherme de Carvalho</given-names>
            <suffix>Neto</suffix>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Funari</surname>
            <given-names>Marcelo Buarque de Gusm&#xE3;o</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <aff id="aff1"><label>1</label>Hospital Israelita Albert Einstein, S&#xE3;o Paulo, SP, Brazil.</aff>
        <aff id="aff2"><label>2</label>Sociedade Brasileira de Diabetes, S&#xE3;o Paulo, SP, Brazil.</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1">Corresponding author: Anneliese Rosmarie Gertrud Fischer Thom &#x2013; Hospital Israelita Albert Einstein, Imagem department, Avenida Albert Einstein, 627/701, 1st sub basement floor, building A &#x2013; Morumbi &#x2013; Zip code: 05652-900 &#x2013; S&#xE3;o Paulo, SP, Brazil &#x2013; Phone: <phone>(55 11) 2151-0489</phone> &#x2013; E-mail: <email>afthom@einstein.br</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Jan-Mar</season>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Jan-Mar</season>
        <year>2014</year>
      </pub-date>
      <volume>12</volume>
      <issue>1</issue>
      <fpage>100</fpage>
      <lpage>105</lpage>
      <history>
        <date date-type="received">
          <day>03</day>
          <month>12</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>05</day>
          <month>12</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p> This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </license-p>
        </license>
      </permissions>
      <abstract>
        <title>ABSTRACT</title>
        <p>The authors report the case of a 70-year-old male patient with chronic lymphoid leukemia who presented subsequently a papillary carcinoma of the thyroid with metastases to regional lymph nodes. The patient was treated with surgical thyroidectomy with regional and cervical lymph node excision and radioiodine therapy (I-131). The protocolar control scintigraphy 4 days after the radioactive dose showed I-131 uptake in both axillae and even in the inguinal regions. PET/CT showed faint FDG-F-18 uptake in one lymph node of the left axilla. An ultrasound guided fine needle biopsy of this lymph node identified by I-131 SPECT/CT and FDG-F-18 PET/CT revealed lymphoma cells and was negative for thyroid tissue and thyroglobulin content. The sequential blood counts done routinely after radiation treatment showed a marked fall until return to normal values of leucocytes and lymphocytes (absolute and relative), which were still normal in the last control 19 months after the radioiodine administration. Chest computed tomography showed a decrease in size of axillary and paraaortic lymph nodes. By immunohistochemistry, cells of the lymphoid B lineage decreased from 52% before radioiodine therapy to 5% after the procedure. The authors speculate about a possible sodium iodide symporter expression by the cells of this lymphoma, similar to some other non-thyroid tumors, such as breast cancer cells.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <title>RESUMO</title>
        <p>Os autores relatam o caso de um paciente de 70 anos com leucemia linf&#xF3;ide cr&#xF4;nica que apresentou subsequentemente um carcinoma papil&#xED;fero da tire&#xF3;ide com met&#xE1;stases para linfonodos regionais. O paciente foi tratado com tireoidectomia total cir&#xFA;rgica com ex&#xE9;rese de linfonodos regionais e cervicais e radioiodoterapia (I-131). A pesquisa de corpo inteiro protocolar de controle 4 dias ap&#xF3;s a dose radioativa mostrou capta&#xE7;&#xE3;o de I-131 em ambas as axilas e mesmo nas regi&#xF5;es inguinais. PET/CT mostrou discreta capta&#xE7;&#xE3;o de FDG-F-18 em um linfonodo da axila esquerda. A bi&#xF3;psia por agulha fina guiada por ultrassom deste linfonodo identificado por SPECT/CT com I-131 e PET/CT com FDG-F-18 revelou c&#xE9;lulas linfomatosas e foi negativa para tecido tireoidiano e conte&#xFA;do de tireoglobulina. Os hemogramas sequenciais feitos rotineiramente ap&#xF3;s tratamento com radia&#xE7;&#xF5;es mostraram uma acentuada queda at&#xE9; retorno aos valores normais de leuc&#xF3;citos e de linf&#xF3;citos (absolutos e relativos), que continuavam normais no &#xFA;ltimo controle 19 meses ap&#xF3;s a administra&#xE7;&#xE3;o do radioiodo. Tomografia computadorizada de t&#xF3;rax mostrou uma redu&#xE7;&#xE3;o em tamanho de linfonodos axilares e para-aorticos. Por imunohistoqu&#xED;mica, as c&#xE9;lulas da linhagem linfoide B decresceram de 52% antes da radioiodoterapia para 5% depois do procedimento. Os autores conjeturam sobre uma poss&#xED;vel express&#xE3;o de <italic>symporter</italic> de iodeto de s&#xF3;dio pelas c&#xE9;lulas deste linfoma, &#xE0; semelhan&#xE7;a de outros tumores n&#xE3;o tireoidianos, tais como c&#xE9;lulas de c&#xE2;ncer da mama.</p>
      </trans-abstract>
      <kwd-group>
        <title>Keywords:</title>
        <kwd>Lymphoma</kwd>
        <kwd>Lymphocyte count</kwd>
        <kwd>Leukemia</kwd>
        <kwd>Thyroid neoplasms/therapy</kwd>
        <kwd>Iodine radioisotopes/therapeutic use</kwd>
        <kwd>Case reports</kwd>
      </kwd-group>
      <counts>
        <fig-count count="8"/>
        <table-count count="2"/>
        <equation-count count="0"/>
        <ref-count count="17"/>
        <page-count count="6"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>It is well known that chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SCLL) predispose to the occurrence of subsequent neoplasms, mainly kidney and skin cancers.<sup>(<xref rid="B1" ref-type="bibr">1</xref>&#x2013;<xref rid="B7" ref-type="bibr">7</xref>)</sup> The association with thyroid carcinoma is extremely rare, according to the medical literature.<sup>(<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>)</sup>
</p>
      <p>We present the case of a patient with chronic lymphocytic leukemia and secondary papillary thyroid carcinoma whose primary neoplasm had an unusual evolution after a single therapeutic dose of I-131 intended to ablate thyroid remnants after total thyroidectomy.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>I.F., a 70-year-old male patient, was diagnosed as having chronic lymphocytic leukemia (CLL) in July 2009. During the staging workup, a huge substernal multinodular goiter, with an estimated volume of 82cm<sup>3</sup> was found by computed tomography (CT). An ultrasound (US) guided fine needle biopsy of one of the nodules was suspicious for thyroid cancer. This suspicion was reinforced by a serum thyroglobulin value of 936.9ng/mL (chemiluminescence immunoassay), measured in October of the same year.</p>
      <p>As for the CLL, no specific treatment had been recommended. However, in view of the above mentioned findings concerning the thyroid, the patient was submitted to total thyroidectomy with regional lymph node (LN) resection in January 5, 2010. A total of 29 LN were excised (5 right paratracheal, 8 from level VI, 5 from level VII on the right side, 7 from level VI and 4 from level VII on the left side).</p>
      <p>The pathological diagnosis of the excised material reported: &#x201C;follicular variant of papillary microcarcinoma of the thyroid in the right lobe, confined to the thyroid gland, measuring 1.2mm, without involvement of surgical margins, extrathyroid tissue, or vascular invasion; multinodular goiter with foci of lymphocytic thyroiditis&#x201D;.</p>
      <p>Metastases were found in 8/29 LN: in all 5 right paratracheal LN and in 3/8 LN of level VI, on the right site. All others were free of disease.</p>
      <p>The patient was referred for internal radiation therapy with I-131, which was planned for February 2010 and was preceded by a whole-body scintigraphy (WBS) one week before. Preparation for WBS and subsequent treatment was instituted during one month according to the international guidelines. The patient had remained without hormone replacement since the surgery.</p>
      <p>In the meantime the following follow-up studies were done, listed with the respective results:</p>
      <list list-type="simple">
        <list-item>
          <label>&#x2013;</label>
          <p>Chest X-ray: normal.</p>
        </list-item>
        <list-item>
          <label>&#x2013;</label>
          <p>US of the cervical region: enlarged LN in levels I, II, and VI bilaterally consistent with an inflammatory reaction.</p>
        </list-item>
        <list-item>
          <label>&#x2013;</label>
          <p>CT of the chest and abdomen: enlarged axillary and retroperitoneal LN, not further investigated and attributed to the underlying lymphocytic leukemia.</p>
        </list-item>
      </list>
      <p>By that time (January 27), his complete blood count showed 4.74x10<sup>6</sup> erythrocytes, 19,200 leukocytes from which 13,958 (72.7%) were lymphocytes, and 265,000 platelets.</p>
      <p>Serum values obtained in January 23 were: TSH: 63mIU/L; thyroglobulin: 93.4ng/mL (963.9ng/mL before surgery); anti-thyroglobulin antibodies: absent.</p>
      <p>I-131 WBS done on January 27, 2010 detected tiny remnants of iodine avid tissue in the anterior cervical region, with 24 hour uptake &lt;1% of the tracer dose. No other definite uptake was seen besides a very faint dubious higher concentration in both axillary regions, which was disregarded (<xref ref-type="fig" rid="f1">Figure 1A</xref>).</p>
      <fig id="f1" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <title>Whole-body scintigraphy before (1A) and 4 days after (1B) therapeutic dose of I-131. Uptake in axillae is suspected in the pre-dose scan but is evident in the post-dose scan. Note uptake also in the inguinal regions</title>
        </caption>
        <graphic xlink:href="1679-4508-eins-12-01-0100-gf01"/>
      </fig>
      <p>A therapeutic dose of 7,400MBq (200mCi) I-131 was administered on February 2, 2010.</p>
      <p>At the routine post-therapeutic WBS done on February 6, in addition to the expected uptake in the cervical remnants, definite uptake in both axillary regions and even in tiny structures in the inguinal regions was seen (<xref ref-type="fig" rid="f1">Figure 1B</xref>). The planar scintigrams were complemented by a SPECT/CT study of the chest, which clearly showed radioiodine concentration in the axillary lymph nodes. At least one enlarged lymph node in the left axilla could be precisely identified (<xref ref-type="fig" rid="f2">Figure 2</xref>).</p>
      <fig id="f2" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <title>SPECT/CT 4 days after I-131 therapy. Beside radioiodine concentration in the surgical remnants of the thyroidectomy, significant uptake is detected in the axillary lymph nodes, mainly in the left axillat axilla</title>
        </caption>
        <graphic xlink:href="1679-4508-eins-12-01-0100-gf02"/>
      </fig>
      <p>Metastatic spread of thyroid carcinoma to the axillary lymphatic chains is a very rare condition and is generally related to advanced disease according to the literature,<sup>(<xref rid="B10" ref-type="bibr">10</xref>&#x2013;<xref rid="B13" ref-type="bibr">13</xref>)</sup> which was not the case of our patient. Another potential mechanism mentioned in the literature is an anomalous lymphatic drainage caused by a complex surgery,<sup>(<xref rid="B10" ref-type="bibr">10</xref>)</sup> which could have been possible in that case.</p>
      <p>On the other hand, the moderate diffuse and bilateral enlargement of the lymph nodes found upon clinical examination was more consistent with lymphoma. A differential diagnosis was imperative for decision-making between surgical or conservative treatment.</p>
      <p>A FDG-F-18 PET/CT revealed only faint metabolic activity in both axillae, slightly more pronounced (SUVmax 1.3) in one nodule on the left side, assumed to be the same that showed the highest radioiodine uptake.</p>
      <p>Because the patient refused open biopsy, a SPECT/CT, PET/CT, and ultrasound-guided fine needle aspiration biopsy of the well-defined left axillary LN was performed. The aspirated material was submitted to cytology, flow cytometry, and dosing of thyroglobulin and anti-thyroglobulin antibodies.</p>
      <p>Cytology analysis reported the absence of epithelial cells and calcification and was consistent with CLL/SCLL.</p>
      <p>Flow cytology/immunophenotypic profile showed CD19+ cells with coexpression of CD5, CD20, CD23 and kappa light chain, being also consistent with CLL/SCLL.</p>
      <p>Thyroglobulin and anti-thyroglobulin antibodies measured in the biopsied tissue by chemiluminescence immunoassay were undetectable.</p>
      <p>Based on these results, thyroid carcinoma metastases were ruled out and adenomegaly by CLL/SCLL was reported.</p>
      <p>As part of the follow-up protocol of radioiodine treatment, sequential blood counts were done weekly between the 3rd and 6th week and eventually at later times after the radioactive dose. Although a transient drop of white blood cells, and particularly lymphocytes, always occurs after radiation therapy, an unusual reduction of the number of leucocytes mainly due to the drop of lymphocytes was seen in this patient. There was a remarkable reduction in the absolute as well as in the relative number of lymphocytes, which returned to normal values and remained normal for up to 19 months (September 2011). In January 24, 2012, leukocyte count was 8,590/mm<sup>3</sup> (100%) and lymphocytes were 3,800/mm<sup>3</sup> (44%), showing a small rise in the relative count beyond the normal upper limit of 40% (<xref ref-type="table" rid="t1">Table 1</xref>, <xref ref-type="fig" rid="f3">Figure 3</xref>).</p>
      <table-wrap id="t1" orientation="portrait" position="float">
        <label>Table 1</label>
        <caption>
          <title>Erythrocyte, leucocyte, lymphocyte and platelet counts in sequential hemograms from immediately before radioiodine therapy until 19 months after the treatment</title>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup width="10%" span="1">
            <col span="1"/>
            <col span="1"/>
            <col span="1"/>
            <col span="1"/>
            <col span="1"/>
            <col span="1"/>
            <col span="1"/>
            <col span="1"/>
            <col span="1"/>
            <col span="1"/>
          </colgroup>
          <thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
            <tr>
              <th align="left" rowspan="2" valign="middle" colspan="1">Date</th>
              <th align="center" style="border-bottom: thin solid;border-color: #000000" valign="middle" rowspan="1" colspan="1">6 days prior I-131</th>
              <th align="center" style="border-bottom: thin solid;border-color: #000000" valign="middle" rowspan="1" colspan="1">I-131 therapy</th>
              <th align="center" colspan="7" style="border-bottom: thin solid;border-color: #000000" valign="middle" rowspan="1">Time after I-131 therapy</th>
            </tr>
            <tr>
              <th align="center" rowspan="1" colspan="1">Jan 27, 2010</th>
              <th align="center" rowspan="1" colspan="1">Feb 2, 2010</th>
              <th align="center" rowspan="1" colspan="1">Mar 6, 2010 4 week</th>
              <th align="center" rowspan="1" colspan="1">Mar 27, 2010 7 week</th>
              <th align="center" rowspan="1" colspan="1">Jul 6, 2010 5 month</th>
              <th align="center" rowspan="1" colspan="1">Oct 20, 2010</th>
              <th align="center" rowspan="1" colspan="1">Jan 14, 2011</th>
              <th align="center" rowspan="1" colspan="1">Sep 17, 2011</th>
              <th align="center" rowspan="1" colspan="1">Jan 24, 2012</th>
            </tr>
          </thead>
          <tbody style="border-bottom: thin solid; border-color: #000000">
            <tr>
              <td align="left" rowspan="1" colspan="1">Erythrocytes /mm<sup>3</sup>
</td>
              <td align="center" rowspan="1" colspan="1">4.74x10<sup>6</sup>
</td>
              <td align="center" rowspan="1" colspan="1">7,400mBq</td>
              <td align="center" rowspan="1" colspan="1">4.32x10<sup>6</sup>
</td>
              <td align="center" rowspan="1" colspan="1">3.87x10<sup>6</sup>
</td>
              <td align="center" rowspan="1" colspan="1">4.08X10<sup>6</sup>
</td>
              <td align="center" rowspan="1" colspan="1">4.54x10<sup>6</sup>
</td>
              <td align="center" rowspan="1" colspan="1">4.28x10<sup>6</sup>
</td>
              <td align="center" rowspan="1" colspan="1">4.58X10<sup>6</sup>
</td>
              <td align="center" rowspan="1" colspan="1">4.58X10<sup>6</sup>
</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Leucocytes/mm<sup>3</sup>
</td>
              <td align="center" rowspan="1" colspan="1">19,000</td>
              <td align="center" rowspan="1" colspan="1">(200 mCi)</td>
              <td align="center" rowspan="1" colspan="1">5,730</td>
              <td align="center" rowspan="1" colspan="1">4,800</td>
              <td align="center" rowspan="1" colspan="1">6,000</td>
              <td align="center" rowspan="1" colspan="1">5,190</td>
              <td align="center" rowspan="1" colspan="1">5,450</td>
              <td align="center" rowspan="1" colspan="1">7,010</td>
              <td align="center" rowspan="1" colspan="1">8,590</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Lymphocytes/mm<sup>3</sup>
</td>
              <td align="center" rowspan="1" colspan="1">13,958</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">1,250</td>
              <td align="center" rowspan="1" colspan="1">1,248</td>
              <td align="center" rowspan="1" colspan="1">859</td>
              <td align="center" rowspan="1" colspan="1">1,520</td>
              <td align="center" rowspan="1" colspan="1">1,150</td>
              <td align="center" rowspan="1" colspan="1">2,240</td>
              <td align="center" rowspan="1" colspan="1">3,800</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Lymphocytes relative count</td>
              <td align="center" rowspan="1" colspan="1">72%</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">21%</td>
              <td align="center" rowspan="1" colspan="1">26%</td>
              <td align="center" rowspan="1" colspan="1">14.3%</td>
              <td align="center" rowspan="1" colspan="1">29.3%</td>
              <td align="center" rowspan="1" colspan="1">27.7%</td>
              <td align="center" rowspan="1" colspan="1">32%</td>
              <td align="center" rowspan="1" colspan="1">44%</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Platelets/mm<sup>3</sup>
</td>
              <td align="center" rowspan="1" colspan="1">265,000</td>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">104,000</td>
              <td align="center" rowspan="1" colspan="1">145,000</td>
              <td align="center" rowspan="1" colspan="1">201,000</td>
              <td align="center" rowspan="1" colspan="1">198,000</td>
              <td align="center" rowspan="1" colspan="1">204,000</td>
              <td align="center" rowspan="1" colspan="1">212,000</td>
              <td align="left" rowspan="1" colspan="1"/>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <fig id="f3" orientation="portrait" position="float">
        <label>Figure 3</label>
        <caption>
          <title>Graphic representation of the sequential leukocyte and lymphocyte counts before and along 19 months after internal radiation therapy with I-131</title>
        </caption>
        <graphic xlink:href="1679-4508-eins-12-01-0100-gf03"/>
      </fig>
      <p>A flow cytometry of the peripheral blood had been performed on September 8, 2009 (before surgery), and was repeated on April 15, 2010 (2 months after I-131). Cells of the lymphoid B lineage (lymphoid B cells) dropped from 52% to 5% respectively.</p>
      <p>Follow-up CT of the chest was also done on April 15, 2010, and compared to the CT from September 8, 2009, and showed a decrease in the number and the dimensions of the axillary lymph nodes (<xref ref-type="fig" rid="f4">Figure 4</xref>), as well as absence of mediastinal and hilar lymphadenomegaly.</p>
      <fig id="f4" orientation="portrait" position="float">
        <label>Figure 4</label>
        <caption>
          <title>Computed tomography before (4A) and 9 weeks after (4B) I-131 therapy. Note the marked reduction of lymph nodes in the left axilla</title>
        </caption>
        <graphic xlink:href="1679-4508-eins-12-01-0100-gf04"/>
      </fig>
      <p>A WBS with I-131 under recombinant TSH (rhTSH) was repeated for follow-up control on February 3, 2011, and was negative for thyroid iodine-avid tissues. Serum TSH, thyroglobulin and antithyroglobulin antibodies measured before the first dose and 48 hours after the second dose of rhTSH yielded, respectively, the following results: TSH &lt;0.05mIU/L and 306mIU/L; thyroglobulin, undetectable at both measurements; anti-thyroglobulin antibodies &lt;5U/mL at both determinations.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>The occurrence of secondary tumors in patients with chronic lymphocytic leukemia is not infrequent and is well-documented. According to the literature, those that occur most often are kidney cancer<sup>(<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>)</sup> and melanoma, among others. Secondary thyroid tumors seem to be rare, as they are found in the literature only as case reports.<sup>(<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>)</sup>
</p>
      <p>Our patient presented a well-differentiated papillary microcarcinoma follicular variant secondary to (or concomitant with) chronic lymphocytic leukemia with regional LN metastases.</p>
      <p>The finding of radioiodine uptake in the axillary lymph nodes was perplexing, since this region normally has no anatomical connection with the vessels departing from the thyroid region. References concerning axillary LN metastases of thyroid tumors are equally limited to case reports, in general of patients with advanced disease.<sup>(<xref rid="B10" ref-type="bibr">10</xref>&#x2013;<xref rid="B13" ref-type="bibr">13</xref>)</sup> One possible manner for this unusual spread could have been the large surgery to remove the intrathoracic goiter, as already mentioned.</p>
      <p>As a matter of fact, FDG-F-18 PET/CT was not properly indicated for differential diagnosis because both types of tumors (CLL/SCLL and papillary thyroid carcinoma) have a rather low metabolic activity. It only ruled out a more aggressive process.</p>
      <p>Ideally, an open biopsy with specimen histology should have been done. Bocian et al.<sup>(<xref rid="B8" ref-type="bibr">8</xref>)</sup> published a case of coinciding metastases of papillary carcinoma and of SCLL in cervical lymph nodes. Reid-Nicholson et al.<sup>(<xref rid="B9" ref-type="bibr">9</xref>)</sup> reported the finding of concurrent papillary thyroid carcinoma and CLL/SCLL in a thyroid nodule. A similar concurrence could explain the radioiodine uptake in the axillary LN of our patient. But one may accept that the fine-needle aspiration biopsy was informative in that it confirmed the presence of lymphoma cells by histology and immunohistochemistry, and was entirely negative for cells of the thyroid lineage as well as for thyroid cell-related substances.</p>
      <p>Beside the contents of the material of the aspiration biopsy taken from a LN that had stored the radioactive isotope, one may hypothesize that there was, indeed, a radioiodine uptake by the lymphoma cells and a consequent radiotherapeutical action because of three additional observations: the drastic drop in white blood cell count, in particular of the lymphocytes which returned to normal values in the sixth-week follow-up after the therapeutic radioiodine dose and remained normal for up to 19 months, becoming only minimally elevated after 24 months; the reduction in size of the axillary and mediastinal LN documented by CT prior to and after radioiodine administration, and the compared blood immunohistochemistry.</p>
      <p>Lymphoma cells are sensitive to the energy of the beta emission of I-131.<sup>(<xref rid="B14" ref-type="bibr">14</xref>)</sup> This is the basis of radioimmunotherapy, where the antibody is the carrier of the radioisotope. But no reference to free radioiodine uptake by lymphoma cells was found in the literature.</p>
      <p>Iodide uptake by thyroid follicular cells and cells of differentiated thyroid carcinoma is mediated by the sodium iodide symporter (NIS), which is responsible for an active co-transport mechanism of the ion across the basolateral membrane.<sup>(<xref rid="B15" ref-type="bibr">15</xref>)</sup>
</p>
      <p>NIS is also known to be expressed by breast cancer<sup>(<xref rid="B16" ref-type="bibr">16</xref>)</sup> and by glioma tumor cells.<sup>(<xref rid="B17" ref-type="bibr">17</xref>)</sup> One may speculate that lymphoma cells eventually might also be able to express NIS and that this might have been a possibility in our patient.</p>
      <p>The documentation of this case is limited by the absence of a histological evaluation of the axillary lymphnode which had concentrated the radioactive agent. Nevertheless the normalization of the white cell count and the reduction in size of the axillary and paraaortic lymph nodes following the therapeutic dose of I-131 suggest that there was indeed a radiotherapeutic effect of the radioiodine on the lymphoma cells. This might be a subject for further research.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Manusow</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Weinerman</surname>
              <given-names>BH</given-names>
            </name>
          </person-group>
          <article-title>Subsequent neoplasia in chronic lymphocytic leukemia</article-title>
          <source>JAMA</source>
          <year>1975</year>
          <volume>232</volume>
          <issue>3</issue>
          <fpage>267</fpage>
          <lpage>269</lpage>
          <pub-id pub-id-type="pmid">47401</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Travis</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Curtis</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Hankey</surname>
              <given-names>BF</given-names>
            </name>
            <name>
              <surname>Fraumeni</surname>
              <given-names>JF</given-names>
              <suffix>Jr.</suffix>
            </name>
          </person-group>
          <article-title>Second cancers in patients with chronic lymphocytic leukemia</article-title>
          <source>J Natl Cancer Inst</source>
          <year>1992</year>
          <volume>84</volume>
          <issue>18</issue>
          <fpage>1422</fpage>
          <lpage>1427</lpage>
          <pub-id pub-id-type="pmid">1512794</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mellemgaard</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Geisler</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Storm</surname>
              <given-names>HH</given-names>
            </name>
          </person-group>
          <article-title>Risk of kidney cancer and other second solid malignancies in patients with chronic lymphocytic leukemia</article-title>
          <source>Eur J Haematol</source>
          <year>1994</year>
          <volume>53</volume>
          <issue>4</issue>
          <fpage>218</fpage>
          <lpage>222</lpage>
          <pub-id pub-id-type="pmid">7957806</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nishikubo</surname>
              <given-names>CY</given-names>
            </name>
            <name>
              <surname>Kunkel</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Figlin</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Belldegrun</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rosen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Elashoff</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>An association between renal cell carcinoma and lymphoid malignancies. A case series of eight patients</article-title>
          <source>Cancer</source>
          <year>1996</year>
          <volume>78</volume>
          <issue>11</issue>
          <fpage>2421</fpage>
          <lpage>2426</lpage>
          <pub-id pub-id-type="pmid">8941014</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hisada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Biggar</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Greene</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Fraumeni</surname>
              <given-names>JF</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Travis</surname>
              <given-names>LB</given-names>
            </name>
          </person-group>
          <article-title>Solid tumors after chronic lymphocytic leukemia</article-title>
          <source>Blood</source>
          <year>2001</year>
          <volume>98</volume>
          <issue>6</issue>
          <fpage>1979</fpage>
          <lpage>1981</lpage>
          <pub-id pub-id-type="pmid">11535538</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dasanu</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Alexandrescu</surname>
              <given-names>DT</given-names>
            </name>
          </person-group>
          <article-title>Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia</article-title>
          <source>MedGenMed</source>
          <year>2007</year>
          <volume>9</volume>
          <issue>4</issue>
          <fpage>35</fpage>
          <lpage>35</lpage>
          <comment>Review</comment>
          <pub-id pub-id-type="pmid">18311385</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Royle</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Baade</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Joske</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Girschik</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Frischi</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study</article-title>
          <source>Br J Cancer</source>
          <year>2011</year>
          <volume>105</volume>
          <issue>7</issue>
          <fpage>1076</fpage>
          <lpage>1081</lpage>
          <pub-id pub-id-type="pmid">21847118</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bocian</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kopczynski</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rieske</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Piaskowski</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Stuszniak</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kupnicka</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Simultaneous occurrence of medullary and papillary carcinomas of the thyroid gland with metastases of papillary carcinoma to the cervical lymph nodes and the coinciding small B-cell lymphocytic lymphoma of the lymph nodes &#x2013; a case report</article-title>
          <source>Pol J Pathol</source>
          <year>2004</year>
          <volume>55</volume>
          <issue>3</issue>
          <fpage>23</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="pmid">15619977</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reid-Nicholson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Moreira</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ramalingam</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Cytologic features of mixed papillary carcinoma and chronic lymphocytic leukemia/small lymphocytic lymphoma of the thyroid gland</article-title>
          <source>Diagn Cytopathol</source>
          <year>2008</year>
          <volume>36</volume>
          <issue>11</issue>
          <fpage>813</fpage>
          <lpage>817</lpage>
          <pub-id pub-id-type="pmid">18831028</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koike</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fujii</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yanaga</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nakagawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yokoyama</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Yahara</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Axillary lymph node recurrence of papillary thyroid microcarcinoma: report of a case</article-title>
          <source>Surg Today</source>
          <year>2004</year>
          <volume>34</volume>
          <issue>5</issue>
          <fpage>440</fpage>
          <lpage>443</lpage>
          <pub-id pub-id-type="pmid">15108084</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ers</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Galant</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Malaise</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rahier</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Daumerie</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Axillary lymph node metastasis in recurrence of papillary thyroid carcinoma: a case report</article-title>
          <source>Wien Klin Wochenschrift</source>
          <year>2006</year>
          <volume>118</volume>
          <issue>3-4</issue>
          <fpage>124</fpage>
          <lpage>127</lpage>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakayama</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wada</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Masudo</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Rino</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Axillary lymph node metastasis from papillary thyroid carcinoma: report of a case</article-title>
          <source>Surg Today</source>
          <year>2007</year>
          <volume>37</volume>
          <issue>4</issue>
          <fpage>311</fpage>
          <lpage>315</lpage>
          <pub-id pub-id-type="pmid">17387564</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kepenekci</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Demirkan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cakmac</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tug</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ekinci</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Axillary lymph node metastasis as a late manifestation of papillary thyroid carcinoma</article-title>
          <source>Thyroid</source>
          <year>2009</year>
          <volume>19</volume>
          <issue>4</issue>
          <fpage>417</fpage>
          <lpage>419</lpage>
          <pub-id pub-id-type="pmid">19355833</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaminski</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Zelenetz</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Press</surname>
              <given-names>OW</given-names>
            </name>
            <name>
              <surname>Saleh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Leonard</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fehrenbacher</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-Cell non-Hodgkin's lymphomas</article-title>
          <source>J Clin Oncol</source>
          <year>2001</year>
          <volume>19</volume>
          <issue>19</issue>
          <fpage>3918</fpage>
          <lpage>3928</lpage>
          <pub-id pub-id-type="pmid">11579112</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Doh&#xE1;n</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>De la Vieja</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Paroder</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Riedel</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Artani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Reed</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The sodium/iodide Symporter (NIS): characterization, regulation and medical significance</article-title>
          <source>Endocr Rev</source>
          <year>2003</year>
          <volume>24</volume>
          <issue>1</issue>
          <fpage>48</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="pmid">12588808</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Renier</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Goris</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Grosh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Katznelson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Noless</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Endogenous NIS expression in triple-negative breast cancers</article-title>
          <source>Ann Surg Oncol</source>
          <year>2009</year>
          <volume>16</volume>
          <issue>4</issue>
          <fpage>962</fpage>
          <lpage>968</lpage>
          <pub-id pub-id-type="pmid">19184238</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carlin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Akabani</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Zalutsky</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>In vitro cytotoxicity of (211) at-astatide and (131) I-iodide to glioma tumor cells expressing the sodium/iodide symporter</article-title>
          <source>J Nucl Med</source>
          <year>2003</year>
          <volume>44</volume>
          <issue>11</issue>
          <fpage>1827</fpage>
          <lpage>1838</lpage>
          <pub-id pub-id-type="pmid">14602867</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
